The 4 drugs tracked here made $29.5B of Bristol Myers Squibb’s 2025 revenue (61%) and lose US exclusivity by 2031. Since 2023, Bristol Myers Squibb has closed 4 acquisitions of $1B or more, worth $24.4B in total. Products from those deals brought in $360M in 2025.
Get an email when anything changes for Bristol Myers Squibb →
Bars are each drug's 2025 sales as a share of Bristol Myers Squibb’s total revenue ($48.2B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Jan 2024 | Mirati TherapeuticsBMS, October 2023 · BMS, January 2024 | $4.8B | Oncology | Krazati, a lung cancer drug, plus early cancer programsPlus a CVR worth up to $1.0B.2025 sales: Krazati $205M BMS FY2025 | Approved product |
| Feb 2024 | RayzeBioBMS, February 2024 | $4.1B | Oncology | RYZ101, a radiopharmaceutical in Phase 3 for neuroendocrine tumors | Pipeline only |
| Mar 2024 | Karuna TherapeuticsBMS, March 2024 | $14.0B | Neuroscience | Cobenfy for schizophrenia, approved by the FDA in September 2024, after the deal closed2025 sales: Cobenfy $155M BMS FY2025 | Pipeline only |
| Dec 2025 | Orbital TherapeuticsBMS, October 2025 · BMS 10-K 2025 | $1.5B | Immunology | OTX-201, an early in vivo CAR-T therapy for autoimmune disease | Pipeline only |
| 4 counted | $24.4B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Bristol Myers Squibb announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Oncology | $12.8B | $8.9B |
| Cardiometabolic | $14.4B | – |
| Neuroscience | – | $14.0B |
| Other | $2.3B | – |
| Immunology | – | $1.5B |
Bristol Myers Squibb has the most revenue at risk in cardiometabolic, but has spent the most on acquisitions in neuroscience. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Bristol Myers Squibb paid, not the sales it will bring in. Only one of the 4 companies it bought was already selling an approved product at closing (Mirati Therapeutics); the rest brought pipeline drugs whose sales are years away and may never arrive. The closest like-for-like figure is sales of the products Bristol Myers Squibb bought: $360M in 2025, against $29.5B of 2025 sales losing US exclusivity by 2037. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: BMS FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Bristol Myers Squibb’s announcement or filing in the table above.
See all 63 drugs on the patent cliff →Breckenridge launched generic pomalidomide under the settlement timeline, with Camber following. Breckenridge